InHANSE Institute of Head and Neck Studies and Education Contact Us

De-ESCALaTE study shows cisplatin superior to cetuximab in treating HPV positive oropharyngeal cancer

Results from our De-ESCALaTE HPV study were today reported in the Lancet. [see paper here -]   The study funded by CRUK has shown that compared with the standard cisplatin treatment is superior to cetuximab.

Our thanks go to all our collaborators and especially to all the patients who took part.  Without their participation into clinical trials this important question would not have been answered.



Charity appeal

Find out more about our £1m Charity appeal for the AcceleraTED cancer Treatment programme.